AU2021226570A1 - Cancer treatment methods - Google Patents

Cancer treatment methods Download PDF

Info

Publication number
AU2021226570A1
AU2021226570A1 AU2021226570A AU2021226570A AU2021226570A1 AU 2021226570 A1 AU2021226570 A1 AU 2021226570A1 AU 2021226570 A AU2021226570 A AU 2021226570A AU 2021226570 A AU2021226570 A AU 2021226570A AU 2021226570 A1 AU2021226570 A1 AU 2021226570A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021226570A
Other languages
English (en)
Inventor
Shelley Erin ACKERMAN
Michael N. ALONSO
David Dornan
Marcin L. KOWANETZ
Robert S. SIKORSKI
Steven A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bolt Biotherapeutics Inc
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of AU2021226570A1 publication Critical patent/AU2021226570A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021226570A 2020-02-25 2021-02-25 Cancer treatment methods Abandoned AU2021226570A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981355P 2020-02-25 2020-02-25
US62/981,355 2020-02-25
US202063105104P 2020-10-23 2020-10-23
US63/105,104 2020-10-23
PCT/US2021/019667 WO2021173832A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Publications (1)

Publication Number Publication Date
AU2021226570A1 true AU2021226570A1 (en) 2022-09-29

Family

ID=75143716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021226570A Abandoned AU2021226570A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Country Status (7)

Country Link
US (1) US20230165968A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110403A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519807A (cg-RX-API-DMAC7.html)
KR (1) KR20220145871A (cg-RX-API-DMAC7.html)
AU (1) AU2021226570A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169117A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021173832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024130003A1 (en) 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CA3221817A1 (en) * 2023-06-30 2025-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Combination therapies for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
AU2017249229A1 (en) * 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
BR112019000071A2 (pt) * 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
TW201834697A (zh) * 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體-藥物結合物之組合療法
US20210154316A1 (en) * 2018-05-17 2021-05-27 Bolt Biotherapeutics, Inc. Immunoconjugates
US20220226492A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting HER2
EP3937984A1 (en) * 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
WO2020190762A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Macromolecule-supported tlr agonists
US20220226491A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1

Also Published As

Publication number Publication date
CA3169117A1 (en) 2021-09-02
EP4110403A1 (en) 2023-01-04
WO2021173832A1 (en) 2021-09-02
JP2023519807A (ja) 2023-05-15
KR20220145871A (ko) 2022-10-31
US20230165968A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CN114502592B (zh) 靶向cldn18.2的抗体及其制备方法和应用
US20230165968A1 (en) Cancer treatment methods
US11400164B2 (en) Immunoconjugates targeting HER2
JP7102670B2 (ja) 抗pd‐l1抗体とil‐7との融合
TWI870335B (zh) 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
EP4273170A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
EP3889172A1 (en) Targeted tgf beta inhibition
KR20200016899A (ko) 활성화가능 항-pdl1 항체, 및 이의 이용 방법
KR20190072626A (ko) 활성화가능한 항-ctla-4 항체 및 그의 용도
WO2018058001A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
KR102608723B1 (ko) 항―pd-1 항체 및 그의 용도
KR20210093270A (ko) 인간화 항-SIRPα 항체
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
KR20210053924A (ko) Egfr을 표적으로 하는 면역접합체
AU2021232158A1 (en) Anti-CD36 antibodies and their use to treat cancer
KR20200088810A (ko) 항―ox40 항체 및 그의 용도
CN115397859A (zh) 治疗癌症和癌症转移的联合疗法
CN118488964A (zh) 抗cd36抗体及其治疗癌症的用途
CN117355331A (zh) 抗Siglec组合物及其用途
CN112423778A (zh) 利用免疫毒素和检查点抑制剂组合的新辅助癌症治疗
WO2024130003A1 (en) Cancer combination treatment method
US20260115307A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
EP4725969A1 (en) Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
HK40100877A (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
AU2024324215A1 (en) Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period